The New York Times @nytimes
AbbVie for years delayed competition for its blockbuster drug Humira, at the expense of patients and taxpayers. The $114 billion monopoly is about to end. Now, it's a case study in how companies artificially prop up prices on their best-selling drugs. https://t.co/OrkbHOFjkd — PolitiTweet.org